Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3

Author(s):  Zur Eyal

Issue:  Sep/Oct 2019 - Volume 23, Number 5
View All Articles in Issue

Page(s):  366-375

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 1
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 2
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 3
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 4
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 5
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 6
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 7
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 8
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 9
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 10

Download in electronic PDF format for $75

Abstract:  Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment) for the topical treatment of leishmania major. Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain. This article represents part 3 of a 3-part article on the topic of cutaneous leishmaniasis. Part 1 discussed the treatment option of amphotericin-B liposomal gel, part 2 discussed the treatment option of paromomycin sulfate liposomal gel, and this final part (3) discusses the treatment option of photodynamic therapy.

Related Keywords: Eyal Zur, BScPharm, RPh, MBA, cutaneous leishmaniasis, leishmania major, leishmania tropica, Israel, topical preparations, photodynamic therapy, daylight activation, photosensitizer, 5-aminolevulinic acid hydrochloride, formulations, amphotericin B liposomal gel, paromomycin sulfate liposomal gel

Related Categories: DERMATOLOGY, EXCIPIENTS, FORMULATIONS, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
Sep/Oct 2019
Pg. 366-375

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
Jul/Aug 2019
Pg. 288-293

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
May/Jun 2019
Pg. 200-207

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

PostScription: Compounding in Israel
Zur Eyal
May/Jun 2009
Pg. 262-263

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
Jan/Feb 2019
Pg. 23-31

Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
Mar/Apr 2019
Pg. 94-104

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
Nov/Dec 2012
Pg. 462-469

The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
Nov/Dec 2001
Pg. 462-464

Topical Use of Sodium Cromoglicate (Cromolyn Sodium) to Treat Atopic Dermatitis and Other Skin Allergies
Zur Eyal
Sep/Oct 2012
Pg. 386-393

Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Zur Eyal
Sep/Oct 2019
Pg. 376-381

Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
Jan/Feb 2014
Pg. 14-19

Hormone Replacement Therapy: Part 1 - The Evolution of Hormone Treatment
Lorentzen Jean
Sep/Oct 2001
Pg. 336-338

Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Israel Alan
May/Jun 2003
Pg. 176-178

Foscarnet 2.5% Topical Cream
Allen Loyd V Jr
Nov/Dec 2007
Pg. 509

Return to Top